Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01974752 · ClinicalTrials.gov registry record · Phase 3
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
A Phase 3 study of Uveal Melanoma and Metastatic, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT01974752 is a Phase 3 study of Uveal Melanoma and Metastatic that has completed, run by AstraZeneca. The registered enrollment target is 152 participants, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target. The trial reports 20 study locations across 10 states.
The verdict
NCT01974752, a Phase 3 study of Uveal Melanoma and Metastatic, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
Selumetinib therapy in patients with metastatic uveal melanoma.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Dacarbazine
- DRUG 75mg selumetinib
Study Locations (20)
Other
- Research Site - Edegem
- Research Site - Ghent
- Research Site - Kortrijk
- Research Site - Leuven
- Research Site - Olomouc
- Research Site - Prague
- Research Site - Hus
- Research Site - Nice
- Research Site - Paris
- Research Site - Heidelberg
- Research Site - München
California
- Research Site - Los Angeles
Colorado
- Research Site - Aurora
Georgia
- Research Site - Atlanta
Maryland
- Research Site - Lutherville
Missouri
- Research Site - St Louis
New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01974752
The ClinicalTrials.gov registry entry for NCT01974752 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uveal Melanoma appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT01974752 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01974752 about?
NCT01974752 is a clinical study titled "Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)". Selumetinib therapy in patients with metastatic uveal melanoma.
What is the current status of trial NCT01974752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2014-04. Estimated completion is 2016-10.
What conditions does trial NCT01974752 study?
This clinical trial studies the following conditions: Uveal Melanoma, Metastatic.
What interventions are being tested in trial NCT01974752?
The interventions under investigation include: placebo (DRUG), Dacarbazine (DRUG), 75mg selumetinib (DRUG).
Who is sponsoring clinical trial NCT01974752?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01974752 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RECRUITING · Phase 3
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.